AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02563834
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin infusion for insulin/glucose clamp procedure
Trial: NCT00319605
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02590055
Drug: gemcitabine/docetaxel combination
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00288652
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00120471
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600-mg tablet taken orally once daily
Trial: NCT00120471
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Trial: NCT00120471
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Trial: NCT01061606
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00679484
Drug: olmesartan medoxomil + candesartan cilexetil placebo
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: tablet; frequency: daily; duration: 24 weeks
Trial: NCT00961480
Drug: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Trial: NCT00961480
Drug: Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Trial: NCT00961480
Drug: Comparator: metformin 1000 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of metformin 1000 mg tablet
Trial: NCT00961480
Drug: Comparator: metformin 850 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of metformin 850 mg tablet
Trial: NCT00431353
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/kg iv bid for 21 days
Trial: NCT00431353
Drug: valganciclovir [Valcyte]
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 900mg po bid for 21 days
Trial: NCT00523640
Drug: combination of gemcitabine, capecitabine, and bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
Trial: NCT03179735
Drug: Cetylpyridinium Chloride 0.7 mg/ml
RxNorm normalized name: cetylpyridinium chloride 0.7 MG/ML
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Trial: NCT00679484
Drug: olmesartan medoxomil placebo + candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: tablets; frequency: daily; duration: 24 weeks
Trial: NCT01603134
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg tablet once a day
Trial: NCT01635777
Drug: Miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day for 12 weeks
Trial: NCT01635777
Drug: Miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day for 8 weeks
Trial: NCT01676220
Drug: HOE901-U300 (new formulation of insulin glargine)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Trial: NCT02707549
Drug: balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)
RxNorm normalized name: magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02707549
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03212495
Drug: dexamedetomidine
DrugBank: Medetomidine (DB11428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Trial: NCT03212495
Drug: neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Trial: NCT06444204
Drug: Rilzabrutinib
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib tablet administered orally
Trial: NCT02996474
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Trial: NCT02996474
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
Trial: NCT00879073
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Trial: NCT01676220
Drug: Lantus (insulin glargine)
RxNorm normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Trial: NCT01310868
Drug: 5-ALA
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
Trial: NCT03664115
Drug: Itraconazole 200 mg
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole 200 mg oral tablet daily, on a 21-day cycle.
Trial: NCT00109551
Drug: zinc sulphate dietary supplement
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00948649
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
Trial: NCT02544737
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
Trial: NCT04147260
Drug: BI 730357
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT04147260
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02700048
Drug: intra-nasal naloxone
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
Trial: NCT02175225
Drug: Deferoxamine Mesylate
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02175225
Drug: Placebo (for Deferoxamine Mesylate)
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02946359
Drug: Crizotinib, bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
Trial: NCT00449163
Drug: Floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00449163
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01107925
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally, daily for 12 days
Trial: NCT01107925
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally, daily for 12 days
Trial: NCT01531192
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50000 unit/3 times a day, both for orally and by orogastric route
Trial: NCT01498913
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
Trial: NCT00658671
Drug: ENMD-2076
RxNorm normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, daily dosing in 28 day cycles
Trial: NCT00762684
Drug: TAK-559
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
Trial: NCT01121718
Drug: ICG Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
Trial: NCT01124747
Drug: 14C-Labeled ASP1585
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT05867056
Drug: IMC-I109V Single Ascending Dose
RxNorm normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of IMC-I109V
Trial: NCT05867056
Drug: IMC-I109V Multiple Ascending Doses
RxNorm normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose administration of IMC-I109V
Trial: NCT02646683
Drug: vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01409239
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 hr IV insulin administered according to hospital guideline
Trial: NCT02391025
Drug: Gallium-68 citrate
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Gallium-68 PSMA (DB16303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via IV at time of imaging
Trial: NCT03889249
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stroke Thrombolytic
Trial: NCT03889249
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stroke Thrombolytic
Trial: NCT00168948
Drug: Sulfadoxin (12.5) Pyrimethamine (250 mg)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02343575
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
Trial: NCT02831023
Drug: Sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
Trial: NCT02831023
Drug: 0.25 mg/kg primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine will be administered in an aqueous solution according to weight-based dosing.
Trial: NCT02831023
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
Trial: NCT02831023
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
Trial: NCT02831023
Drug: Amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
Trial: NCT00198991
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antileukemic drug
Trial: NCT00198991
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT00198991
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytostatic drug
Trial: NCT00198991
Drug: Asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT02343575
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
Trial: NCT04482959
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
Trial: NCT04482959
Drug: Sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiological solution will be used as placebo
Trial: NCT00198991
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytostatic drug
Trial: NCT00198991
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Growth factor
Trial: NCT00198991
Drug: Vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT00329810
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, oral, 15 mg, once daily, 12 weeks.
Trial: NCT03767829
Drug: ALN-AAT02
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
Trial: NCT03767829
Drug: ALN-AAT02
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
Trial: NCT03824938
Drug: Aspirin 650mg Oral Capsule
RxNorm normalized name: aspirin 650 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
Trial: NCT03824938
Drug: Acetaminophen Tablet 650mg
RxNorm normalized name: acetaminophen Chewable Tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
Trial: NCT00847080
Drug: Sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin phosphate 100 mg per day per 2 weeks
Trial: NCT02046629
Drug: Teriflunomide HMR1726
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT02046629
Drug: cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:power Route of administration: oral
Trial: NCT00419081
Drug: Forodesine Hydrochloride Sterile Solution, 5 mg/mL
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT00419081
Drug: Forodesine Hydrochloride Capsules (100 mg)
RxNorm normalized name: doxepin
DrugBank: Forodesine (DB06185)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00198991
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytostatic drug
Trial: NCT01262027
Drug: Dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
Trial: NCT01318395
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
Trial: NCT00052000
Drug: MLN2704 (DM1 conjugated monoclonal antibody MLN591)
RxNorm normalized name: Conjugated Estrogens
DrugBank: MLN2704 (DB06513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00821717
Drug: Normal saline (0.9%)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
Trial: NCT04472637
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 mg, as one tablet /day for 24 weeks.
Trial: NCT00198991
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT00198991
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT00198991
Drug: Teniposide
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT00198991
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug